Jeffrey Yu

CMO Jeff Yu buys 158,730 shares at $0.63; stock down 85.8% from $4.22 high; 2 other insiders bought in past 14 days

Jeffrey Yu, Chief Medical Officer, purchased 158,730 shares at $0.63 on 2026-06-23, bringing holdings to 8,780,410 shares, as ONMD trades at $0.60—down 85.8% from its 52-week high of $4.22. This buy arrives amid severe recent price deterioration (−33.6% over 30 days, −30.7% over 90 days) and follows a cluster pattern: 2 other insiders also bought within the past 14 days. Yu's prior trades at this ticker show 3 of 3 prior buys were well-timed at the 90-day mark, with gains of +128.2%, +130.4%, and +151.6% on those respective purchases. However, the company's fundamentals remain pressured—latest quarter revenue was $96,000 ($96.0K), net income −$2,453,000 (−$2.5M), and the firm was unprofitable over its most recent full fiscal year despite annual revenue growth of +111.4%. The insider's demonstrated precision on prior ONMD trades and the multi-insider buy pattern warrant observation, though the stock's acute drawdown from its 52-week peak and persistent negative earnings create substantial uncertainty about the market's current pricing.

CMO Jeffrey Yu bought 172,414 shares of ONMD at $0.58; stock now $0.50. Cluster buy with 2 other insiders in 14 days, but stock down 88.2% from 52-week high.

Jeffrey Yu, Chief Medical Officer, purchased 172,414 shares at $0.58 on 2026-06-16 as part of a cluster buy pattern (2 other insiders also bought within 14 days). His prior trades at ONMD show a pattern of well-timed entries: 4 of 4 prior buys achieved positive 90-day returns (range +26.5% to +50.5%). However, the current market context is severely adverse—the stock is trading at $0.50, down 88.2% from its 52-week high of $4.22, down 40.6% in 30 days, and down 39.0% in 90 days. The company remains unprofitable ($-2.5M net income) despite 111.4% annual revenue growth, with a market cap of $27.2M. The timing signal from prior ONMD buys is not yet clear for this transaction, as the 90-day outcome is unmeasurable. Cluster activity combined with historical pattern warrants monitoring, but the severe price deterioration and persistent unprofitability present material offsetting risks.

ONMD Chief Medical Officer bought 903,614 shares at $0.83 for $750.0K, extending prior pattern: 5 of 5 recent purchases at this ticker well-timed post-trade.

Yu Jeffrey, Chief Medical Officer, purchased 903,614 shares at $0.83 on 2026-04-01, increasing his holdings to 8.45M shares (+12.0%). This transaction is noteworthy because his prior trading history at OneMedNet—five consecutive purchases made in September 2025—all delivered positive 90-day returns, ranging from +26.5% to +50.5%, indicating consistent timing success at this specific ticker. His cross-ticker track record reinforces this pattern, with 95.00% of his 20 prior open-market buys producing positive 90-day returns and an average 90-day return of +64.7%. The current market price of $1.10 is +27.1% above his April transaction price in the 30-day window, aligning with his historical performance. However, the company remains fundamentally challenged: it posted a quarterly revenue of $177.0K, a net loss of $-741.0K, and unprofitable full-year results, despite strong annual revenue growth of +111.4%. The timing signal is clear, but underlying profitability remains a material concern for investors.

CMO Yu Jeffrey purchased 22,762 shares (22.8K) across 22 trades from Dec 2023–Jan 2024 at blended avg $0.76.

Yu Jeffrey, Chief Medical Officer of OneMedNet Corp, executed 22 separate purchases totaling 22,762 shares for $17,192.08 over a seven-week period (Dec 8, 2023 – Jan 30, 2024), with a blended average price of $0.76. The stock now trades at $1.42, representing a 86.8% gain from the weighted entry point, though the company faces material headwinds: latest quarterly revenue of $177,000.00 ($177.0K) against net income of $-741,000.00 ($-741.0K), and annual revenue contracted -37.0% year-over-year. His prior 5 trades at ONMD have all yielded strong 30-day returns (ranging +128.2% to +156.2%), suggesting consistent buy-point selection at this ticker, though none yet have 90-day outcomes to assess. This accumulation—adding 22,762 shares to holdings of 2,500,124 shares pre-transaction—occurs as the stock has fallen -54.8% from its 52-week high despite a +79.0% rebound over the past 90 days, creating conflicting signals about valuation and momentum.

CMO Yu Jeffrey acquired 9,540 shares totaling $8,928.68 across 21 purchases (blended avg $0.94), expanding 2.75M holdings by 0.3%.

Yu Jeffrey, Chief Medical Officer, executed 21 separate open-market purchases of ONMD shares between February and December 2024, accumulating 9,540 shares for $8,928.68 at a blended average price of $0.94—well below the current price of $1.42. His cross-ticker track record shows 20 prior buys with a 77.78% 90-day win rate and average 90-day return of +56.9%, indicating consistent timing discipline across multiple stocks. However, at ONMD specifically, his 5 most recent prior trades (all in late September 2025) have not yet achieved measurable 90-day outcomes, and his ONMD historical timing shows 0 of 0 prior buys were well-timed at the 90-day mark. The company's fundamentals remain challenged: latest quarterly revenue of $177.0K, net income of $-741.0K, annual revenue contraction of -37.0%, and full-year unprofitability, set against a market cap of $72.4M. This persistent accumulation despite deteriorating operational metrics and sector weakness suggests either contrarian conviction in a turnaround or mechanical execution unrelated to fundamental recovery signals.

CMO Yu Jeffrey bought 2,010,479 shares (2.01M) for $959,585.63 over 18 transactions at blended avg $0.48; holdings grew 37.8% to 7,326,223 shares.

Yu Jeffrey, Chief Medical Officer at OneMedNet Corp, executed 18 separate purchases totaling 2,010,479 shares for $959,585.63 at a blended average price of $0.48, increasing his stake by 37.8% from 5,315,744 to 7,326,223 shares across a three-month window from June through September 2025. The stock currently trades at $1.42 (-54.8% from its 52-week high of $3.14 and down 37.7% over the last 30 days), but is up 79.0% over 90 days from its entry period. The company operates with negative unit economics (latest quarter revenue of $177,000.00 against net income of $-741,000.00) and has experienced severe annual revenue contraction of -37.0%, creating a highly speculative backdrop for this significant insider capital deployment. Notably, at his prior five buys at ONMD, only 2 of 5 achieved positive 90-day returns, suggesting mixed execution timing at this specific ticker despite his cross-ticker track record averaging +63.8% 30-day returns across 20 prior open-market purchases.